GEP20247587B - Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy - Google Patents
Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathyInfo
- Publication number
- GEP20247587B GEP20247587B GEAP201715070A GEAP2017015070A GEP20247587B GE P20247587 B GEP20247587 B GE P20247587B GE AP201715070 A GEAP201715070 A GE AP201715070A GE AP2017015070 A GEAP2017015070 A GE AP2017015070A GE P20247587 B GEP20247587 B GE P20247587B
- Authority
- GE
- Georgia
- Prior art keywords
- nephropathy
- immunoglobulin
- methods
- human subject
- subject suffering
- Prior art date
Links
- 208000010159 IgA glomerulonephritis Diseases 0.000 title 1
- 201000001474 proteinuria Diseases 0.000 title 1
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract 1
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Diabetes (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407979P | 2016-10-13 | 2016-10-13 | |
| US15/399,524 US10736960B2 (en) | 2016-01-05 | 2017-01-05 | Methods for inhibiting fibrosis in a subject in need thereof |
| US15/470,647 US20170253667A1 (en) | 2016-01-05 | 2017-03-27 | Methods for inhibiting fibrosis in a subject in need thereof |
| US201762527926P | 2017-06-30 | 2017-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20247587B true GEP20247587B (en) | 2024-01-25 |
Family
ID=61906454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201715070A GEP20247587B (en) | 2016-10-13 | 2017-10-12 | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP3525798A4 (pt) |
| JP (1) | JP6893554B2 (pt) |
| KR (1) | KR102348939B1 (pt) |
| CN (2) | CN116726163A (pt) |
| AU (1) | AU2017342428B2 (pt) |
| BR (1) | BR112019007426A2 (pt) |
| CA (2) | CA3039927C (pt) |
| CL (2) | CL2019000909A1 (pt) |
| GE (1) | GEP20247587B (pt) |
| IL (1) | IL265981A (pt) |
| JO (1) | JOP20190068A1 (pt) |
| MA (1) | MA46541A (pt) |
| MX (1) | MX2019004074A (pt) |
| PH (1) | PH12019500711A1 (pt) |
| SG (1) | SG11201902941UA (pt) |
| UA (1) | UA126908C2 (pt) |
| WO (1) | WO2018071701A1 (pt) |
| ZA (1) | ZA201902933B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419860A (zh) * | 2020-03-19 | 2020-07-17 | 长春市儿童医院 | 一种肾小球分叶状肾病造模方法 |
| CN115215937B (zh) * | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | 抗人masp-2抗体及其制备方法和应用 |
| CN117016486B (zh) * | 2023-07-20 | 2024-05-14 | 上海澎立生技医药研究有限公司 | 一种IgA肾病合并膜性肾病的动物模型构建方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE024996T2 (en) * | 2003-05-12 | 2016-01-28 | Helion Biotech Aps | Anti-MASP-2 antibodies |
| US20140056873A1 (en) * | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7626730B2 (en) * | 2006-03-31 | 2009-12-01 | Eastman Kodak Company | Method of making a multilevel halftone screen |
| CA2971474C (en) * | 2009-10-16 | 2022-11-22 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| US9102721B2 (en) * | 2011-01-21 | 2015-08-11 | Fibrogen, Inc. | Therapeutic method |
| NZ709997A (en) * | 2011-04-08 | 2016-03-31 | Univ Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| US9644035B2 (en) * | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| ME03755B (me) * | 2011-05-04 | 2021-04-20 | Omeros Corp | Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa |
| WO2014144542A2 (en) * | 2013-03-15 | 2014-09-18 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| ES2829913T3 (es) * | 2013-10-17 | 2021-06-02 | Omeros Corp | Procedimientos de tratamiento de afecciones asociadas con la activación del complemento dependiente de MASP-2 |
| AU2017205453B2 (en) * | 2016-01-05 | 2020-03-12 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
-
2017
- 2017-06-16 JO JOP/2019/0068A patent/JOP20190068A1/ar unknown
- 2017-10-12 EP EP17861108.3A patent/EP3525798A4/en active Pending
- 2017-10-12 SG SG11201902941UA patent/SG11201902941UA/en unknown
- 2017-10-12 GE GEAP201715070A patent/GEP20247587B/en unknown
- 2017-10-12 CA CA3039927A patent/CA3039927C/en active Active
- 2017-10-12 CN CN202310450575.2A patent/CN116726163A/zh active Pending
- 2017-10-12 AU AU2017342428A patent/AU2017342428B2/en active Active
- 2017-10-12 CA CA3210384A patent/CA3210384A1/en active Pending
- 2017-10-12 CN CN201780060710.5A patent/CN110177557A/zh active Pending
- 2017-10-12 BR BR112019007426A patent/BR112019007426A2/pt active Search and Examination
- 2017-10-12 WO PCT/US2017/056386 patent/WO2018071701A1/en unknown
- 2017-10-12 MX MX2019004074A patent/MX2019004074A/es unknown
- 2017-10-12 MA MA046541A patent/MA46541A/fr unknown
- 2017-10-12 UA UAA201904866A patent/UA126908C2/uk unknown
- 2017-10-12 JP JP2019520140A patent/JP6893554B2/ja active Active
- 2017-10-12 KR KR1020197012865A patent/KR102348939B1/ko active IP Right Grant
-
2019
- 2019-04-01 PH PH12019500711A patent/PH12019500711A1/en unknown
- 2019-04-04 CL CL2019000909A patent/CL2019000909A1/es unknown
- 2019-04-11 IL IL265981A patent/IL265981A/en unknown
- 2019-05-10 ZA ZA2019/02933A patent/ZA201902933B/en unknown
- 2019-11-28 CL CL2019003485A patent/CL2019003485A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019500711A1 (en) | 2019-11-18 |
| SG11201902941UA (en) | 2019-05-30 |
| CN116726163A (zh) | 2023-09-12 |
| BR112019007426A2 (pt) | 2019-07-02 |
| UA126908C2 (uk) | 2023-02-22 |
| JP6893554B2 (ja) | 2021-06-23 |
| NZ753260A (en) | 2021-11-26 |
| JOP20190068A1 (ar) | 2019-04-01 |
| CL2019000909A1 (es) | 2019-06-14 |
| CL2019003485A1 (es) | 2020-04-13 |
| CA3039927A1 (en) | 2018-04-19 |
| CA3210384A1 (en) | 2018-04-19 |
| AU2017342428B2 (en) | 2021-02-04 |
| KR20190063475A (ko) | 2019-06-07 |
| IL265981A (en) | 2019-06-30 |
| ZA201902933B (en) | 2023-05-31 |
| MA46541A (fr) | 2019-08-21 |
| CN110177557A (zh) | 2019-08-27 |
| EP3525798A1 (en) | 2019-08-21 |
| KR102348939B1 (ko) | 2022-01-12 |
| MX2019004074A (es) | 2019-06-10 |
| WO2018071701A1 (en) | 2018-04-19 |
| EP3525798A4 (en) | 2020-07-08 |
| JP2019534271A (ja) | 2019-11-28 |
| AU2017342428A1 (en) | 2019-05-23 |
| CA3039927C (en) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001878A (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
| GB201804136D0 (en) | Providing out-of-band verification for blockchain transactions | |
| AU2019268074A1 (en) | Methods for treating hepcidin-mediated disorders | |
| EP3280200A4 (en) | Method for performing ranging related operation in wireless communication system | |
| KR20180084886A (ko) | 음료 제조기, 음료 제조기를 구비한 시스템, 이를 작동시키기 위한 방법 | |
| NZ727020A (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
| EP3136169A4 (en) | Light source system, and projection system and method | |
| DK3131585T3 (da) | Multidentate, bifunktionelle chelateringsmidler til radionuklidkompleksdannelse i diagnostik og terapi | |
| SG11201704160XA (en) | Antibodies, uses & methods | |
| EP3157294A4 (en) | Method for controlling timing advance for direct communication between terminals in wireless communication system, and apparatus therefor | |
| GEP20247587B (en) | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy | |
| MX2017011454A (es) | Procesos para preparar fluorocetólidos. | |
| SG11202002314WA (en) | Polishing solution, polishing solution set, and polishing method | |
| KR101556994B9 (ko) | 수전시공지그 | |
| DK3070964T3 (da) | Høreapparat, især hørehjælpeapparat. | |
| GB2590331B (en) | Balanced, symmetrical coil | |
| DK2993275T3 (da) | Pumpestation, spildevandssystem og fremgangsmåde til at transportere spildevand | |
| PH12017500071A1 (en) | Therapeutic agent for keratoconjunctive disorder | |
| EP3218826A4 (en) | System for cross-host, multi-thread session alignment | |
| KR101860073B9 (ko) | 수전시공지그 | |
| MX2017003728A (es) | Sistema mejorador de sabor. | |
| GB201501594D0 (en) | Mobile transaction validation | |
| IL274432B (en) | Headtracking for parametric binaural output system and method | |
| HUP1600486A2 (en) | Smart mobile cabinet, especially saddle cabinet | |
| GB201601412D0 (en) | Financial transaction lifestyle quality scoring system |